Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
about
Clinical molecular imaging with radiotracers: current statusIn-vivo biodistribution and safety of 99mTc-LLP2A-HYNIC in canine non-Hodgkin lymphomaPredicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomabAstatine Radiopharmaceuticals: Prospects and ProblemsImproving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapyNoninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosisDendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.The evolving role of nuclear molecular imaging in cancer.A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.Engineering therapeutic monoclonal antibodies.Albumin-Templated Manganese Dioxide Nanoparticles for Enhanced Radioisotope Therapy.
P2860
Q26994741-143276AF-8905-4CC8-9B31-0B45501E4D9CQ27305229-BEB06F61-7547-4035-A8DB-B5F0B5B3CA8AQ33392939-3F5E564F-D1D2-454C-8324-AE09AA6BA593Q33640550-754AE349-8594-411F-BE7D-4D61B37915FAQ33645793-679C8F3C-66D6-4B32-8BED-34E22715B477Q34089324-B472D120-1388-48A7-AD66-96318D2BDAF7Q35509695-626B6CF8-5522-47E5-955E-10E225DAAF61Q36690711-589C1BFA-B91D-4E45-A9F3-763055E2C2E4Q37011086-079A7456-FD2F-42B0-B687-D9EADD085A09Q37169112-3AE4A22E-6305-4A11-905F-2E972B8CF899Q37174938-D268F11E-E96C-4263-B06D-08DE0EAA66BAQ38795442-336C1C36-6EF9-44D8-A463-D618D5B20D39Q39009271-6C609074-C0E5-41D6-975A-538FE292C503Q42961805-450ABCD8-8E1C-47B3-A6D3-5C66CD8123CCQ47820029-CF7E07BF-8E68-4923-ADD4-9B1630BE9201Q53267635-CE94C834-75B5-4C0C-8CEA-5A2F2FC85DF5
P2860
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I
@nl
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
@ast
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
@en
type
label
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I
@nl
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
@ast
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
@en
prefLabel
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I
@nl
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
@ast
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
@en
P2860
P356
P1433
P1476
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
@en
P2093
A J Davies
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210378
P407
P577
2007-05-01T00:00:00Z
P5875
P6179
1050456992